Floatz logo

Advate

Hemophilia A

Runhui WUUNKNOWNPhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
74/ 100
Competitive Position
73/ 100

Competitive context

61 Active assets in the Hemophilia A cohort.

Asset / SponsorPhaseRating
Turoctocog Alfa
Novo Nordisk A/S
Phase 4A
Eptacog Alfa (Activated)
AryoGen Pharmed Co.
Phase 4A
Rurioctocog Alfa Pegol
Takeda
Phase 4BBB
bay94-9027
Bayer
Phase 4BBB
Immunoglobulin G4 [230-Proline,De-449-Lysine], Anti-(Human Blood-Coagulation Factor Ix)(Human Clone 0365-0001-9985 ?4-Chain), Disulfide With Human Clone 0365-0001-9985 ?-Chain, (228?226?),(231?229?)-Bis(Disulfide) With Anti-(Human Blood-Coagulation Factor X) Immunoglobulin G4 [228-Proline,405-Leucine,409-Lysine,De-447-Lysine] (Human Clone 0365-0001-8174 ?4-Chain) Disulfide With Human Clone 0365-0001-8174 ?-Chain
Novo Nordisk A/S
Phase 3BBB

View all 44 →

Same molecule, other indications

Advate is also rated in:

severe hemophilia ADormant
BB
Indicative · Phase 3
67 / 100
View asset →
hemophiliaDormant
B
Indicative · Phase 3
60 / 100
View asset →
inherited blood coagulation disorderDormant
CC
Indicative · Phase 1
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →